Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LYT-300 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| LYT-300 | DRUG | A prodrug of allopregnanolone, a small molecule drug |
| Placebo | OTHER | Placebo for LYT-300 |
LYT-300 is an investigational small molecule developed by PureTech Health plc. It is designed to deliver allopregnanolone, a hormone, and has been studied in a Phase 1/Phase 2 trial in healthy volunteers. The specific therapeutic indications for LYT-300 have not been disclosed.
LYT-300 targets allopregnanolone, a naturally occurring hormone. The drug is a small molecule designed to deliver allopregnanolone. Its mechanism relates to this hormone target rather than to a receptor or enzyme class.
LYT-300 is being developed by PureTech Health plc, a biopharmaceutical company whose ticker symbol is PRTC. PureTech Health is the sponsor of the clinical program for LYT-300.
LYT-300 is in Phase 2 development. It is an investigational drug and has not been approved by the FDA. The completed trial was a Phase 1/Phase 2 study, and the program remains in clinical development.
LYT-300 has been studied in one completed clinical trial, NCT05129865, titled LYT-300 in Healthy Volunteers. That Phase 1/Phase 2 trial enrolled 186 participants and was an uncontrolled study without randomization or double blinding. No active trials are currently listed.